当前位置:药药网 / 数据中心 /变体注释摘要_体外和功能分析类型
苯妥英钠-mephenytoin
变量_单倍型
CYP2C19*1, CYP2C19*19
记事
A mutation for CYP2C19*1C (991A > G) was introduced using pcDNA3.1/CYP2C19*1A as a template, resulting in pcDNA3.1/CYP2C19*1C (*1B and *1C is used interchangeably in the article). Mutations for CYP2C19*19 (991A>G and 151A>G) was successively introduced using pcDNA3.1/CYP2C19*1C as a template. All CYP2C19 plasmids were sequenced to confirm successful mutagenesis. The cDNAs of CYP2C19*1C, CYP2C19*19 were subsequently subcloned into the pGYR1 yeast expression vector and heterologously expressed in yeast cells and proteins were purified from yeast microsomes. Proteins were then assayed for catalytic activity. Kinetic parameters were estimated using Michaelis-Menten plots and mephenytoin hydroxylation was assayed by HPLC.
专家论述
CYP2C19 *19 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in yeast microsomes heterologously expressing CYP2C19*19 as compared to CYP2C19 *1.